

Row No	REC no	IRAS no	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
1	16/WS/0114	200445	CHIL 5253	Yes	28/10/2019	14	76	90	08/05/2019	30/07/2019	27/09/2016	12/08/2019	13/08/2019	28/08/2019		
2	17/EE/0327	224081	REDJUVENATE	No		21			07/02/2017	18/07/2019	20/11/2017	18/01/2018	08/08/2019	28/04/2020	F - No patients seen	Neither
3	17/LO/0980	219505	HALT - Stereotactic Body Radiotherapy for the treatment of OPD	Yes	43784	21	100	121	22/02/2018	17/07/2019	10/07/2017	19/08/2019	07/08/2019	23/08/2019		
4	17/LO/1875	219487	Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)	Yes	43843	28	47	75	05/04/2017	30/10/2019	08/01/2018	05/11/2019	27/11/2019	11/12/2019		
5	17/SC/0039	220282	MAGPIE	No					21/10/2019	12/02/2020	18/04/2017				B - Suspended by sponsor	Neither
6	17/SC/0476	186573	MERIT	No		104			14/11/2018	06/09/2019	07/11/2017	04/10/2019	19/12/2019	23/10/2019	F - No patients seen	Neither
7	18/EE/0275	229033	(COMBIVAS)	Yes	44097	26	203	229	27/05/2019	07/02/2020		25/02/2020	04/03/2020		B - Suspended by sponsor	Neither
8	18/EM/0406	250403	The EURO-SHOCK Trial version 1	Yes	43899	27	130	157	03/10/2018	04/10/2019	04/03/2019	30/10/2019	31/10/2019	05/11/2019	F - No patients seen	Neither
9	18/ES/0119	245233	Stopping Aminosaliclylate Therapy in Inactive Crohn's Disease (STATIC)	No		101			07/11/2018	28/10/2019	09/11/2018	17/01/2020	06/02/2020		B - Suspended by sponsor	Neither
10	18/LO/0660	237150	REMAP-CAP	Yes	43955	5	6	11	07/04/2020	23/04/2020	23/07/2018	23/04/2020	28/04/2020	29/04/2020	D - Sponsor Delays	Sponsor
11	18/LO/1290	249002	Hookipa H-100-002	No		60			12/01/2018	25/11/2019	06/11/2018	20/01/2020	24/01/2020	29/01/2020	B - Suspended by sponsor	Neither
12	18/NE/0052	234786	Avacopan in Patients with C3 Glomerulopathy	No					25/07/2019	17/12/2019	24/04/2018				B - Suspended by sponsor	Neither
13	18/NW/0031	230387	NET-02	No					10/03/2018	04/03/2020	08/02/2018	03/03/2020			B - Suspended by sponsor	Neither
14	18/NW/0694	248847	Derby - Geographic Atrophy secondary to AMD	Yes	43880	15	119	134	03/09/2019	08/10/2019	07/12/2018	21/10/2019	23/10/2019	09/12/2019		
15	18/NW/0765	250220	Testing a novel aid to diagnosis of peritonitis in clinic v1	Yes	44017	0	146	146	21/08/2018	10/02/2020	01/04/2019	07/02/2020	10/02/2020		B - Suspended by sponsor	Neither
16	18/SC/0427	220853	The Bronchiolitis Endotracheal Surfactant Study (BESS)	Yes	43782	27	16	43	10/07/2019	01/10/2019	15/10/2018	03/10/2019	28/10/2019	13/11/2019	C - Closed by sponsor	Sponsor
17	18/SC/0472	234266	ProMPT-2	No		14			28/05/2019	14/02/2020	24/10/2018	11/02/2020	28/02/2020		B - Suspended by sponsor	Neither
18	18/SC/0580	235355	FROSTTIE	No					19/02/2020	02/06/2020	19/12/2018				B - Suspended by sponsor	Neither
19	18/SC/0644	242136	AVENUe	No		61			22/02/2019	29/08/2019	19/02/2019	18/11/2019	29/10/2019	11/12/2019	D - Sponsor Delays	Sponsor
20	18/SS/0079	226923	PRECISION	No		22			08/02/2018	15/07/2019	20/08/2018	15/07/2019	06/08/2019	11/09/2019		
21	18/SS/0120	233867	DENIM / DENDritic cell Immunotherapy for Mesothelioma	No		1			28/09/2017	08/10/2019	08/10/2019	09/10/2019	09/10/2019	15/10/2019		
22	18/WA/0199	108978	Azithromycin Therapy for Chronic Lung Disease of Prematurity	Yes	43747	21	2	23	19/06/2018	16/09/2019	29/06/2018	17/09/2019	07/10/2019	08/10/2019		
23	18/WA/0262	245893	CL140FSGS	No		4			29/03/2019	11/07/2019		07/07/2019	15/07/2019	20/11/2019	F - No patients seen	Neither

Row No	REC no	IRAS no	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
24	19/EE/0200	265253	Investigating tirzepatide versus semaglutide in Type 2 Diabetes	Yes	43801	28	62	90	22/07/2019	03/09/2019	29/07/2019	30/09/2019	01/10/2019	01/10/2019		
25	19/EE/0286	255237	Mepolizumab for COPD Hospital Eosinophilic admissions Pragmatic trial1	No		10			13/09/2019	04/02/2020	12/12/2019	11/02/2020	14/02/2020		F - No patients seen	Neither
26	19/EE/0327	270157	inRange	No					22/10/2019	10/03/2020	13/02/2020				B - Suspended by sponsor	Neither
27	19/EM/0060	260387	Study of cemdisiran in adult patients with IgAN	Yes	43853	0	182	182	22/01/2019	25/07/2019	04/02/2019	21/06/2019	25/07/2019	01/08/2019	D - Sponsor Delays	Sponsor
28	19/EM/0063	253607	AMADEUS	Yes	43945	91	98	189	06/02/2019	18/10/2019	14/05/2019	09/01/2020	17/01/2020	22/01/2020	B - Suspended by sponsor	Neither
29	19/EM/0201	261499	Diagnostic pathways for patients with chronic breathlessness.	Yes	43774	27	62	89	22/03/2019	08/08/2019	08/09/2019	19/07/2019	04/09/2019	05/09/2019	D - Sponsor Delays	Sponsor
30	19/EM/0221	261147	Feasibility of low energy diet in HFpEF and type 2 diabetes	No		148			19/02/2019	01/10/2019		23/01/2020	26/02/2020	28/02/2020	B - Suspended by sponsor	Neither
31	19/EM/0258	266702	Fluids Exclusively Enteral from Day 1 (FEED1)	Yes	43796	27	7	34	10/09/2019	24/10/2019	13/09/2019	04/11/2019	20/11/2019	21/11/2019		
32	19/EM/0267	262581	SPACE FOR COPD maintenance	Yes	43789	0	41	41	11/11/2018	10/10/2019	10/10/2019	10/10/2019	10/10/2019	16/10/2019		
33	19/EM/0282	242364	ARTEMIS-IGAN	No					27/08/2019	24/02/2020					B - Suspended by sponsor	Neither
34	19/EM/0290	263656	Home-based exercise in Renal Transplant patients: The ECSERT Study	Yes	43899	9	39	48	15/04/2019	21/01/2020	14/10/2019	23/01/2020	30/01/2020	30/01/2020		
35	19/EM/0299	265496	Real-time Remote Echo Mentoring	No		12			09/07/2019	27/02/2020	24/02/2020	20/08/2019	10/03/2020	10/03/2020		
36	19/EM/0315	258745	P-VECT Study	No					16/06/2019	17/07/2019	18/11/2019				B - Suspended by sponsor	Neither
37	19/EM/0334	257450	Safety and Activity of Sparsentan in the Treatment of IgA Nephropathy	No					29/11/2019	08/01/2020	07/01/2020				D - Sponsor Delays	Sponsor
38	19/LO/0128	234820	Iron and Muscle	Yes	43691	5	30	35	16/01/2019	10/07/2019	07/03/2019	07/03/2019	15/07/2019	06/08/2019		
39	19/LO/0343	255538	The PRECISE study	Yes	43872	36	69	105	13/08/2019	29/10/2019	12/08/2019	23/10/2019	04/12/2019	05/12/2019		
40	19/LO/0553	257627	GALACTIC-1 Phase 2b study in idiopathic pulmonary fibrosis (IPF)	Yes	43850	69	91	160	13/08/2019	13/08/2019	24/09/2019	21/10/2019	21/10/2019	31/10/2019	F - No patients seen	Sponsor
41	19/LO/0571	256756	Benralizumab Exacerbation Study	No		0			23/11/2018	08/10/2019	22/01/2020	08/10/2019	08/10/2019	17/01/2020	F - No patients seen	Neither
42	19/LO/0738	258589	TURING	No		21			28/10/2019	07/02/2020	14/06/2019		28/02/2020		B - Suspended by sponsor	Neither
43	19/LO/0855	260338	NKTR-214 Phase II urothelial cancer with low PD-L1 expression Study	Yes	43857	4	125	129	13/02/2019	20/09/2019	27/06/2019	11/09/2019	24/09/2019	21/10/2019		
44	19/LO/0966	262945	Provention Bio's T1D Trial Evaluating C-Peptide with Teplizumab	No		2			05/08/2019	04/02/2020		05/11/2019	06/02/2020	11/03/2020		
45	19/LO/0981	260202	IMMU-132-09	No		209			07/05/2019	20/08/2019	16/08/2019	10/03/2020	16/03/2020	20/03/2020	B - Suspended by sponsor	Neither
46	19/LO/0995	263661	Acceptability and tolerance study of Alfamino with HMOs	Yes	43801	5	68	73	26/07/2019	20/09/2019	24/06/2019	17/09/2019	25/09/2019	26/09/2019		

Row No	REC no	IRAS no	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
47	19/LO/1024	263894	Pembrolizumab ? SBRT in Medically Inoperable Stage I/IIA NSCLC	No		56			13/03/2019	02/08/2019	26/07/2019	25/09/2019	27/09/2019	01/11/2019	D - Sponsor Delays	Sponsor
48	19/LO/1270	261294	Cerclage after full dilatation caesarean section	Yes	43829	14	81	95	15/08/2019	26/09/2019	20/09/2019	19/09/2019	10/10/2019	10/10/2019		
49	19/LO/1500	269558	BASIC Study PMCF	No		79			12/09/2019	30/10/2019	29/10/2019	05/12/2019	17/01/2020	21/01/2020	B - Suspended by sponsor	Neither
50	19/LO/1921	271139	Belantamab Mafodotin in newly diagnosed multiple myeloma	No		34			15/08/2019	05/02/2020	03/02/2020	25/02/2020	10/03/2020		B - Suspended by sponsor	Neither
51	19/NE/0110	257719	Precision medicine with zibotentan in microvascular angina (PRIZE)	No					07/10/2019	04/03/2020	04/12/2019				B - Suspended by sponsor	Neither
52	19/NE/0235	260081	Phase 3 Trial of Balixafortide in Patients with HER2 -ve Breast Cancer	No		120			25/02/2019	23/09/2019	13/01/2020	02/01/2020	21/01/2020	19/02/2020	B - Suspended by sponsor	Neither
53	19/NW/0021	234848	BIOTIPRA Feasibility Trial	Yes	43858	3	187	190	07/03/2019	22/07/2019	06/03/2019	22/07/2019	25/07/2019	15/10/2019	D - Sponsor Delays	Sponsor
54	19/NW/0302	255677	VIP Study	Yes	43886	100	34	134	21/05/2019	14/10/2019	05/07/2019	29/10/2019	22/01/2020	23/01/2020	B - Suspended by sponsor	Neither
55	19/NW/0519	266942	COPE- WEL	No		180			05/09/2019	05/09/2019	23/09/2019	29/01/2020	03/03/2020		B - Suspended by sponsor	Neither
56	19/NW/0570	234906	Efficacy and safety of LNPO23 compared with rituximab in iMN	No		0			22/03/2019	05/12/2019	28/10/2019	28/11/2019	05/12/2019	28/01/2020		
57	19/SC/0021	249552	OPTIMAS Trial	Yes	43837	28	109	137	03/04/2019	23/08/2019	04/04/2019	06/09/2019	20/09/2019	08/11/2019	D - Sponsor Delays	Sponsor
58	19/SC/0107	237804	ANICCA-Class II	No		28			14/02/2018	17/10/2019	05/07/2019	01/11/2019	14/11/2019	18/11/2019		
59	19/SC/0221	259880	Phase I/IIa study to evaluate CCS1477 in haem. malignancies v1.0	Yes	43844	7	111	118	14/02/2019	18/09/2019	10/06/2019	24/09/2019	25/09/2019	04/10/2019		
60	19/SC/0418	261435	The RESET study - version 1.0	Yes	43895	52	56	108	16/09/2019	18/11/2019	24/09/2019	07/01/2020	09/01/2020	14/01/2020	B - Suspended by sponsor	Neither
61	19/SC/0566	265559	WAX	Yes	44076			194	21/02/2020	21/02/2020	02/12/2019	30/06/2020			B - Suspended by sponsor	Neither
62	19/SS/0067	260562	BSET-Conformable EndoVascular Aneurysm Repair (CLEVAR) registry v1.0	No		21			11/09/2019	23/12/2019	30/05/2019	09/01/2020	13/01/2020	05/03/2020	B - Suspended by sponsor	Neither
63	19/SW/0093	260867	BMS11073	No		45			03/10/2018	19/08/2019	17/06/2019	20/09/2019	03/10/2019	28/10/2019		
64	19/WA/0325	266292	EASY-AS	No		67			13/08/2019	19/12/2019	02/12/2019	16/01/2020	24/02/2020	04/03/2020	F - No patients seen	Neither
65	19/WM/0097	246910	Project MURRAY: Feasibility Study	No					25/04/2019	22/07/2019					B - Suspended by sponsor	Neither
66	19/WM/0178	262396	Multi-sited, mainstreaming of the term Snuby? to all types of births	Yes	43808	15	26	41	04/03/2019	29/10/2019	25/07/2019	29/10/2019	13/11/2019	13/11/2019		
67	19/WM/0308	268333	Exercise as an anti-inflammatory treatment in axial spondyloarthritis (axSpA): a proof of concept study	No					17/06/2019	30/03/2020	29/10/2019				B - Suspended by sponsor	Neither

Row No	REC no	IRAS no	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Reasons for Delay	Reasons for delay correspond to:
68	19/WS/0188	270378	ARISE-HF	No					05/03/2020	05/03/2020	14/02/2020				B - Suspended by sponsor	Neither
69	19/YH/0094	256470	Protocol 18-513 Andexanet ICH	No		20			30/04/2019	04/07/2019	19/06/2019	27/06/2019	24/07/2019	09/08/2019		
70	19/YH/0229	266822	Efficacy and Safety of Benralizumab in Moderate to Very Severe COPD	No		166			13/08/2019	13/09/2019	07/09/2019	29/01/2020	26/02/2020	02/03/2020	B - Suspended by sponsor	Neither
71	19/YH/0269	259860	The 'SIT and be FIT' study - Version 1.0	Yes	43832	52	31	83	11/09/2019	11/10/2019	09/09/2019	13/11/2019	02/12/2019	05/12/2019		
72	19/YH/0400	271539	DIAMOND Study	No					29/01/2020	29/01/2020	09/01/2020	25/06/2020			B - Suspended by sponsor	Neither
73	20/EE/0101	281712	RECOVERY trial	Yes	43927	14	6	20	17/03/2020	17/03/2020	17/03/2020	13/03/2020	31/03/2020	31/03/2020		
74	20/EM/0003	269023	SurfON	Yes	44077	112	70	182	27/09/2019	05/03/2020	14/02/2020	12/06/2020	25/06/2020		B - Suspended by sponsor	Neither
75	20/HRA/1696	282338	RECOVERY - Respiratory Support	Yes	43944	11	3	14	08/04/2020	09/04/2020	03/04/2020	20/04/2020	20/04/2020	21/04/2020	F - No patients seen	Neither
76	20/NW/0168	281317	SARS-CoV-2 infection	Yes	43927	9	12	21	16/03/2020	16/03/2020	17/03/2020	24/03/2020	25/03/2020	25/03/2020	F - No patients seen	Neither
77	20/SC/0153	271051	The ASTUTE Trial	No					24/03/2020	12/05/2020					B - Suspended by sponsor	Neither
78	20/SC/0201	282769	COVID-19 - ACCORD-2	Yes	44020	12	57	69	29/04/2020	30/04/2020	28/04/2020	07/05/2020	12/05/2020	19/05/2020		
79	20/SS/0057	281986	STOP-COVID19	Yes	44025	38	31	69	05/05/2020	05/05/2020	22/05/2020	05/06/2020	12/06/2020		F - No patients seen	Neither
80	20/WM/0117	276905	Dapagliflozin, Exercise Training and physical function: the DETA trial	No					29/01/2020	10/06/2020	02/06/2020				B - Suspended by sponsor	Neither
81	20/WM/0153	282437	COVID-MASK_v1.0	No		5			12/05/2020	04/06/2020	02/06/2020	09/06/2020	09/06/2020	10/06/2020		
82	20/WS/0062	256875	ACCEPTANCE, version 1	No					20/05/2020	04/06/2020	20/05/2020				B - Suspended by sponsor	Neither
83	20/WS/0070	275797	FINEARTS-HF (Finerenone trial in patients with Heart Failure)	No					21/04/2020	17/06/2020					B - Suspended by sponsor	Neither
84	20/YH/0123	263968	The CONTROL Study	No					11/09/2019	04/06/2020	01/06/2020				B - Suspended by sponsor	Neither
85	20/YH/0177	273999	SALT - The effect of increased sodium intake with a carbohydrate-rich meal on glucose homeostasis in subjects without diabetes after bariatric surgery.	No					06/02/2020	07/05/2020	29/06/2020				D - Sponsor Delays	Neither